JT is the one who said EU exclusivity could be as much as 13 years... but, 10 years and I believe 1 additional year for a new indication. Then again by that time there should be a one a day version...one that Mochida is supposed to be testing. We may not know everything that AMRN could do to extend its patents or protect their franchise.
You are correct that GILD's drug is not very effective at all... certain cell therapies may have better results. Can't wait to see what Vascepa may do with COVID-19 or the inflammation the virus causes through the Endothelial cells.
News 
Market Data 
Discover 
